Figure 1




Figure 2




Figure 3a




Figure 3b




Figure 4




Figure 5






Figure 6


SI
10
8
6
4
2
0
0
0.05
0.5
5
50
PRCLT Recall (µg/mL)
PBS
SEQ ID No.1


SI
10
8
6
4
2
0
0
0.05
0.5
5
50
DNMV Recall (µg/mL)
PBS
SEQ ID No.17



SI
10
8
6
4
2
0
0
0.01
0.1
1
FVIII (µg/mL)
PBS
SEQ ID No.1
SEQ ID No.17

Figure7

Figure 7a: anti-FVIII antibody titres at day28:




Figure 7b: anti-FVIII antibody titres at day56:




Figure 8




Bethesda like units
100
80
60
40
20
0
PBS
SEQ ID1/SEQ ID17
PBS
SEQ ID1/SEQ ID17

Figure 9


SI FVIII
**
****
****
SI
6
4
2
0
0
0.01
0.1
1
0
0.01
0.1
1
PBS Pretreatment
P1/P17 Pretreatment
FVIII restimulation (µg/mL)



Bethesda units
0
1
2
3
4
PAP 133-152
SEQ ID No. 1/SEQ ID No. 17
Week 3
Week 5
Week 7
Week 9
Week 13
*

Figure 10